52273-79-7

Usage

Uses

Used in Pharmaceutical Research:
2-(3-Aminophenyl)acetic acid ethyl ester is used as a chemical intermediate for the synthesis of pharmaceutical drugs, contributing to the development of new medications.
Used in Organic Synthesis:
In the field of organic synthesis, 2-(3-Aminophenyl)acetic acid ethyl ester is used as a reagent to facilitate the production of other compounds, playing a crucial role in chemical reactions.
Used in Research Studies:
2-(3-Aminophenyl)acetic acid ethyl ester is utilized in research to study its pharmacological properties and explore its potential therapeutic uses, aiding in the advancement of medical knowledge.

Upstream product

• 64-17-5 ethanol 
• 14338-36-4 3-amino phenylacetic acid 
• 408507-75-5 N-(3-cyanomethyl-phenyl)-acetamide 
• 14318-64-0 ethyl (3-nitrophenyI)acetate 
• 6329-95-9 benzoyloxy-(3-nitro-phenyl)-acetic acid ethyl ester 
• 497-19-8 sodium carbonate 
• 99-05-8 meta-aminobenzoic acid 
• 1877-73-2 3-nitro-benzeneacetic acid 

Downstream Products

• 14338-36-4 3-amino phenylacetic acid 
• 52273-77-5 2-(3-aminophenyl)ethan-1-ol 
• 929519-99-3 C₂₁H₂₂Cl₂N₂O₅S 
• 109572-40-9 (+/-)-(cis-3-amino-cyclohexyl)-acetic acid 
• 109572-40-9 (+/-)-(trans-3-amino-cyclohexyl)-acetic acid 
• 863702-21-0 (3-[(5-bromo-furan-2-carbonyl)-amino]-phenyl)-acetic acid ethyl ester 
• 80216-33-7 3-(allylamino)phenylacetic acid 
• 200214-35-3 3-(Boc-amino)phenylacetic acid ethyl ester 
• 897373-28-3 3-ethoxycarbonylmethylphenylhydrazine 
• 897373-37-4 (3-hydrazinophenyl)acetic acid ethyl ester hydrochloride 
• 1190391-39-9 ethyl (3-{[(benzyloxy)carbonyl]amino}phenyl)acetate 
• 1190391-38-8 benzyl [3-(2-oxobut-3-en-1-yl)phenyl]carbamate 
• 441285-17-2 (3-{[(benzyloxy)carbonyl]amino}phenyl)acetic acid 
• 1190391-40-2 benzyl (3-{2-[methoxy(methyl)amino]-2-oxoethyl}phenyl)carbamate 

Relevant academic research and scientific papers

Hapten design and monoclonal antibody to fluoroacetamide, a small and highly toxic chemical

Fluoroacetamide (FAM) is a small (77 Da) and highly toxic chemical, formerly used as a rodenticide and potentially as a poison by terrorists. Poisoning with FAM has occurred in humans, but few reliably rapid detection methods and antidotes have been reported. Therefore, producing a specific antibody to FAM is not only critical for the development of a fast diagnostic but also a potential treatment. However, achieving this goal is a great challenge, mainly due to the very low molecular weight of FAM. Here, we design two groups of FAM haptens for the first time, maximally exposing the fluorine or amino groups, with the aid of linear aliphatic or phenyl-contained spacer arms. Interestingly, whereas the hapten with fluorine at the far end of the hapten did not induce an antibody response to FAM, the hapten with an amino group at the far end and phenyl-contained spacer arm triggered a significantly specific antibody response. Finally, a monoclonal antibody (mAb) named 5D11 was successfully obtained with an IC50 value of 97 μg mL?1 and negligible cross-reactivities to the other nine functional and structural analogs.

SYMMETRICAL TRIS-ARYL-AMIDE DERIVATIVES AND THEIR USE AS ANTI-HEPARANASE

The present invention relates to tris-aryl-amide derivatives having an anti-heparanase activity, in particular it relates to ureido/thioureido/ether tris-aryl-amide derivatives of formula The invention also relates to the use of such compounds as a medica

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA

Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-molecule cancer immunotherapy. New hybrids of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that respectively target IDO1 and DNA were rationally designed. As the first-in-class examples of such molecules, they were found to exhibit significantly enhanced anticancer activity in vitro and in vivo with low toxicity. This proof-of-concept study has established a critical step toward the development of a novel and effective immunotherapy for the treatment of cancers.

Development of triarylsulfonamides as novel anti-inflammatory agents

Triaylsulfonamides were identified as novel anti-inflammatory agents, acting by inhibition of RANKL and TNFα signaling. Structure-activity studies led to the identification of compounds with in vitro potencies of 50 >50 μM). A representative compound (4k, ABD455) was able to completely prevent inflammation in vivo in a prevention model and was highly effective at controlling inflammation in a treatment model.

BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl sulfonamides and related compounds (collectively referred to herein as "BPSAAA compounds"), as described herein, and including, for example, biphenyl-4-sulfonic acid (hydroxyalkyl-phenyl)-amides and related compounds. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment and/or prevention, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of, inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activation in rheumatoid arthritis, osteoporosis, cancer associated bone disease, Paget's disease and the like.

N-Phenyl-N′-(2-chloroethyl)ureas (CEUs) as potential antineoplastic agents. Part 3: Role of carbonyl groups in the covalent binding to the colchicine-binding site

In the course of the development of N-phenyl-N′-(2-chloroethyl)ureas (CEUs) as potential antineoplastic agents, we investigated the effect of carbonylated substituting chains of the aromatic ring of CEU on their covalent binding to the colchicine-binding site (C-BS). In this study, we found that CEU, 5e, 5f, 8e, and 8f substituted by either a methyl ester or a methyl ketyl group at the ω-position exhibited a significant antiproliferative activity on HT-29, M21, and MCF-7 tumor cells. SDS-PAGE assays and cell cycle analysis confirmed that 5e, 5f, 8e, and 8f covalently bind to the C-BS and arrest the cell division in G2/M phase. Surprisingly, the presence of ω-carboxyl, ω-ethyl esters or ω-amides decreased significantly both the antiproliferative activity and the specificity toward β-tubulin.

ENZYME MODULATORS AND TREATMENTS

Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hypervascularization are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein ab1 kinase protein, bcr-ab1 kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein comprises the step of contacting said kinase protein with the novel compounds.

Synthesis of novel phenylacetic acid derivatives with halogenated benzyl subunit and evaluation as aldose reductase inhibitors

In the course of our ongoing studies several substituted benzyloxyphenylacetic acids were prepared. Comparison of their aldose reductase inhibition with the biological activity obtained for recently evaluated benzoic acid analogues revealed the critical role of a methylene spacer between the aromatic core and the acidic function. Starting from the most potent derivative (i.e. 5d, IC50 = 20.9 μM) further structural modifications were performed and their influence on the inhibitory effect was established.

2,3-Diphenylpropionic acids as potent VLA-4 antagonists

2,3-Diphenylpropionic acid derivatives as highly potent VLA-4 antagonists are described. One representative compound, 9cc has inhibited intercellular adhesion by a VCAM-1/VLA-4 interaction with an IC50 of 1.7 nM, and has good pharmacokinetics a

EP2 RECEPTOR AGONISTS

A compound of Formula (I) or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of Formulae (Ai), (Aii), (Aiii) D is selected from Formulae (Di), (Dii), (Diii), (Div), (Dv) B is selected from the group consisting of Formulae (Bi), (Bii), (Biii), (Biv) (Bv).